

# 1 CARE: a novel wearable-derived feature linking 2 circadian amplitude to human cognitive functions

3 Shuya Cui<sup>1,2#</sup>, Qingmin Lin<sup>3#</sup>, Yuanyuan Gui<sup>1,2</sup>, Yunting Zhang<sup>4</sup>, Hui Lu<sup>1,2</sup>, Hongyu Zhao<sup>5</sup>, Xiaolei  
4 Wang<sup>1,2\*</sup>, Xinyue Li<sup>6\*</sup>, Fan Jiang<sup>3,7,8\*</sup>

## 5 Affiliations

6 <sup>1</sup>State Key Laboratory of Microbial metabolism, Joint International Research Laboratory of Metabolic  
7 & Developmental Sciences, Department of Bioinformatics and Biostatistics, School of Life Sciences  
8 and Biotechnology, Shanghai Jiao Tong University, Shanghai, China.

9 <sup>2</sup>SJTU-Yale Joint Center for Biostatistics and Data Science, School of Life Science and Biotechnology,  
10 Shanghai Jiao Tong University, Shanghai, China.

11 <sup>3</sup>Developmental and Behavioral Pediatrics, Pediatric Translational Medicine Institution, Shanghai  
12 Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

13 <sup>4</sup>Developmental and Behavioral Pediatrics, Child Health Advocacy Institute, Shanghai Children's  
14 Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

15 <sup>5</sup>Department of Biostatistics, Yale University, New Haven, CT, United States.

16 <sup>6</sup>School of Data Science, City University of Hong Kong, Hong Kong SAR, China.

17 <sup>7</sup>MOE-Shanghai Key Laboratory of Children's Environmental Health, Xinhua Hospital, School of  
18 Medicine, Shanghai Jiao Tong University, Shanghai, China.

19 <sup>8</sup>Shanghai Center for Brain Science and Brain-Inspired Technology, Shanghai, China.

20

21 <sup>#</sup>Shuya Cui and Qingmin Lin have contributed equally to this work.

22

23 **\*Corresponding Authors**

- 24 Xiaolei Wang, School of Life Science and Biotechnology, Shanghai Jiao Tong University, 800  
25 Dongchuan Rd. Shanghai 200240, China. Email: [thundawner@sjtu.edu.cn](mailto:thundawner@sjtu.edu.cn)
- 26 Xinyue Li, School of Data Science, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon,  
27 Hong Kong SAR 999077, China. Email: [xinyueli@cityu.edu.hk](mailto:xinyueli@cityu.edu.hk)
- 28 Fan Jiang, Developmental and Behavioral Pediatrics, Pediatric Translational Medicine Institution,  
29 Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, 1678  
30 Dongfang Rd. Shanghai 200127, China. Email: [fanjiang@shsmu.edu.cn](mailto:fanjiang@shsmu.edu.cn)

## 31 **Abstract**

32 Circadian rhythms play a critical role in regulating physiological and behavioral processes, with  
33 amplitude being a key parameter for their characterization. However, accurately quantifying circadian  
34 amplitude in natural settings remains a challenge, as traditional melatonin methods require lab settings  
35 and are often costly and time-consuming. Wearable devices are a promising alternative as they can  
36 collect consecutive 24-h data for multiple days. The most commonly used measure of circadian  
37 amplitude from wearable device data, relative amplitude, is subject to the masking effect of behaviors  
38 and fails to leverage the rich information in high-dimensional data, as it only uses the sum of activity  
39 counts in time windows of pre-specified lengths. Therefore, in this study, we firstly proposed a pipeline  
40 to derive a novel feature to characterize circadian amplitude, named circadian activity rhythm energy  
41 (CARE), which can well address the above-mentioned challenges by decomposing raw accelerometer  
42 time series data, and then we validated the new feature CARE by assessing its correlation with  
43 melatonin amplitude (Pearson's  $r = 0.46$ ,  $P = 0.007$ ) in a dataset of 33 healthy participants. Secondly,  
44 we investigated its association with cognitive functions in two datasets: an adolescent dataset (Chinese  
45 SCHEDULE-A,  $n = 1,703$ ) and an adult dataset (the UK Biobank dataset,  $n = 92,202$ ), and we found  
46 that the CARE was significantly associated with the Global Executive Composite ( $\beta = 28.02$ ,  $P = 0.016$ )  
47 in adolescents, and reasoning ability (OR = 0.01,  $P < 0.001$ ), short-term memory (OR = 3.42,  $P <$   
48  $0.001$ ), and prospective memory (OR = 11.47,  $P < 0.001$ ) in adults. And finally, we explored the causal  
49 relationship using Mendelian randomization analysis in the adult dataset. We identified one genetic  
50 locus with 126 SNPs associated with CARE using genome-wide association study (GWAS), of which  
51 109 variants were used as instrumental variables to conduct causal analysis. The results suggested that  
52 CARE had a significant causal effect on reasoning ability ( $\beta = -59.91$ ,  $P < 0.0001$ ), short-term memory  
53 ( $\beta = 7.94$ ,  $P < 0.0001$ ), and prospective memory ( $\beta = 16.85$ ,  $P < 0.0001$ ). The findings suggested that  
54 CARE is an effective wearable-based metric of circadian amplitude with a strong genetic basis and

55 clinical significance, and its adoption can facilitate future circadian studies and potential interventions  
56 to improve circadian rhythms and cognitive functions.

## 57 **Introduction**

58 Circadian rhythms synchronized by the rotation of the Earth are 24-h self-sustained oscillations that  
59 can influence a range of physiological responses and behavioral processes, such as hormone secretion  
60 and sleep-wake cycles[1-5]. The circadian rhythms are regulated by a complex transcriptional feedback  
61 loop involving the “core circadian clock” in the suprachiasmatic nucleus (SCN) of the hypothalamus  
62 and the other peripheral clocks throughout the body[6, 7]. Rhythmic fluctuations driven by the core  
63 clock could be illustrated as a sinusoidal curve with a period of about 24 hours[8], and hence the  
64 circadian rhythms are typically described using three key parameters (**Supplementary Figure 1**):  
65 period (the length of one cycle), phase (the timing of a reference point in the cycle relative to a fixed  
66 event), and amplitude (the difference between crest and trough values of the cycle)[9]. While methods  
67 for measuring period[10, 11] and phase[12-17] are well-established and accurate in both laboratory  
68 and field studies, assessing circadian amplitude remains challenging.

69 Although there is no accepted gold standard for measuring the circadian amplitude[18], the amplitude  
70 of pineal hormone melatonin has been used as one of its reliable biomarkers, and changes in the  
71 melatonin amplitude are also observed in forced desynchrony studies [19, 20]. However, assessing the  
72 melatonin amplitude requires a melatonin profile of at least 24 hours with continuous collection of  
73 blood or saliva samples[21]. Given that the collection protocol of melatonin is costly, labor-intensive,  
74 and infeasible for large population studies and intensive follow-up cohort studies in natural settings,  
75 researchers have attempted to find alternative methods to characterize circadian amplitude using  
76 wearable sensor data[22, 23].


77 Wearable devices can continuously monitor the physical activity of an individual for multiple days in  
78 a natural environment, and thus can solve the challenges present in melatonin sampling. The main  
79 rationale is based on the biological knowledge that both the melatonin rhythms and rest-  
80 activity cycles are strongly influenced by the core circadian clock and hence they may share similar

81 oscillation patterns[8]. Nevertheless, accelerometer data also have some drawbacks. A major challenge  
82 is that the wearable device-derived circadian amplitude is influenced by voluntary behavioral changes  
83 in the natural environment that are not related to circadian rhythms[12, 17, 18]. More importantly, the  
84 most commonly used accelerometer-derived measure, relative amplitude, is calculated solely based on  
85 the differences between the highest and lowest activity counts[22, 24], which has lost rich information  
86 of the high-dimensional activity data. Furthermore, the direct relationship between the circadian  
87 amplitude characterized by accelerometer data and the circadian amplitude depicted by melatonin data  
88 has not been well studied. Thus, it is critical to establish and validate a sound method for extracting  
89 accurate information about circadian amplitude from high-dimensional accelerometer data to fully  
90 leverage the rich high-dimensional information without the masking effect of behaviors.

91 Changes in the amplitude of melatonin have been widely observed in age-related cognitive  
92 impairments and neurodegenerative diseases[9, 25-28]. However, few studies investigated the  
93 association between circadian amplitude and cognitive function in general population. Given that the  
94 circadian rhythms vary greatly during adolescence and many mental disorders also first appear in the  
95 adolescent stage[29, 30], and that the circadian rhythms are susceptible to heavy life and work during  
96 adulthood, it is necessary to examine the correlation between circadian amplitude and cognitive  
97 performance at these stages of life[31]. Furthermore, currently there is no evidence to support a causal  
98 relationship between circadian amplitude and cognitive performance[9, 32]. One prior study tried to  
99 study the causal relationship, but it only measured the relative amplitude and found that it was only  
100 associated with a small number of genetic variants that could not be used to investigate the causal  
101 relationship using Mendelian randomization (MR) analysis[33]. Thus, it is necessary to develop a  
102 metric of circadian amplitude to well capture circadian amplitude information with a strong genetic  
103 basis and clinical relevance, which can allow us to infer the causal relationship between circadian  
104 rhythms and cognitive functions.

105 Therefore, in this study we developed a new amplitude metric for circadian rhythms based on the  
106 accelerometer data and explored its clinical potential in two large-scale databases with different age  
107 groups. The workflow chart is shown in **Figure 1**. First, we proposed a pipeline to derive a new metric  
108 called circadian activity rhythm energy (CARE) which can remove the influence of behavioral factors  
109 using spectral analysis approaches, and then we validated the new metric CARE with the melatonin  
110 amplitude. Secondly, we applied CARE to two accelerometer datasets with 1,703 adolescents and  
111 92,202 adults, respectively, to examine the relationship between CARE and cognitive functions.  
112 Finally, we explored the causal relationship between CARE and cognitive performance through a  
113 genome-wide association study (GWAS) and MR causal analysis.

## Proposing a pipeline to calculate a novel feature called “CARE”



**Figure 1. Workflow chart of the study.**

CARE: circadian activity rhythm energy

\*We also selected the significant loci that were associated with the relative amplitude. However, only three single nucleotide polymorphisms (SNPs) were found, the number of which was too small to conduct further causal analysis.

## 114 Results

### 115 A novel wearable-derived measure of circadian amplitude: CARE

116 In this paper, we developed a pipeline to extract a novel metric CARE (i.e., circadian activity rhythm  
117 energy) to accurately quantify the circadian amplitude at a large scale with low costs. CARE can extract



118 the circadian feature via acceleration signal decomposition, circadian sub-signal extraction, and energy  
119 estimation of the sub-signals from accelerometer data (details shown in **Figure 2**).

120 The accelerometer data can be considered as a composition of sub-signals with different frequencies.  
121 In order to characterize circadian rhythms with behavioral masking effects removed, we decomposed  
122 the data of activity counts and extracted the sub-signals with a period of ~24 hours to represent the  
123 endogenous circadian oscillation. Among a list of signal decomposition approaches such as Fourier  
124 and wavelet analyses, we chose singular spectrum analysis (SSA, see a detailed description in **Figure**  
125 **2c**) in our study for its data adaptive property[34, 35] and better performance compared to other  
126 methods such as Fourier and wavelet transform (detailed results can be found in **Supplementary**  
127 **Method**). Inspired by previous decomposition analysis on accelerometer data[23, 36], we used the  
128 relative energy of the circadian sub-signal with respect to the original signal as a novel estimate of the  
129 circadian amplitude. For a discrete-time signal  $x(t)$ , energy is defined as the envelope of squared signal  
130 magnitude:


131 
$$\text{Energy} = \langle x(t), x(t) \rangle = \sum_{t_0}^{t_0+T} (x(t))^2,$$

132 where  $t_0$  is the starting time point of  $x(t)$  and  $T$  is the time span of  $x(t)$ . The unit of  $x(t)$  and  
133 energy are (activity counts)/minute and (activity count)<sup>2</sup>/minute<sup>2</sup>, respectively.

134 In summary, CARE is calculated using the following equation:

135 
$$\text{CARE} = \frac{\text{Energy of 24-hour signal}}{\text{Total energy of activity signal}} = \frac{\sum_{i \in I} \|X_i\|_F^2}{\|X\|_F^2},$$

136 where  $\|X_i\|_F^2$  is Frobenius norm of the  $i$ th sub-signal,  $I$  is the subset of indices corresponding to the 24-  
137 hour signal, and  $\|X\|_F^2$  is Frobenius norm of the raw activity signal. It should be noted that CARE is  
138 expressed as a ratio ranging from 0 to 1 and is unitless. Furthermore, to effectively capture the dominant  
139 temporal scales and variability in the accelerometer data, and to obtain a reliable estimate of the  
140 autocovariance matrix feature, we required a minimum input data length of three days to calculate the  
141 CARE metric.



**Figure 2. Pipeline to derive the novel measure circadian activity rhythm energy (CARE) from accelerometer data.**

(a) Actogram to show 7 days of wrist accelerometer activity of a single participant. (b) A visual representation of the raw activity signal and the singular spectrum analysis (SSA) decomposed signals, including the base signal (i.e., the first sub-signal indicating the non-periodic trend with the largest energy among all sub-signals), the 24-hour signal, and the behavioral noise signal (i.e., sum of the sub-signals with periods < 24 hours). We can obtain the raw activity signal by adding these three signals together. (c) The graphical display of SSA algorithm. Specifically, the activity time series  $X_N$  of length  $N$  could be decomposed using SSA as follows. First, we chose an appropriate window length  $L$  such that  $2 \leq L \leq \frac{N}{2}$ . Then,  $X_N$  was transferred into a trajectory matrix with  $K$  lagged vectors of  $X_L$  as given by  $T$ , where  $K = N - L + 1$ . The trajectory matrix  $T$  was decomposed by singular value decomposition. By grouping the eigentriples and averaging the elements of reconstructed trajectory matrix along anti diagonals, we could get filtered time series represented by  $G_N = \{g_1, g_2, \dots, g_N\}$ .


		The melatonin dataset	The adolescent dataset (Chinese SCHEDULE-A)	The adult dataset (UK Biobank)
<b>Participants</b>				
n		33	1,703	92,202
Sex	Females (%)	48.45	48.6	56.4
Age (year)	Mean (SD)	34.18 (9.26)	14.59 (1.98)	56.16 (7.82)
<b>Accelerometer data</b>				
Length (day)	Mean (SD)	7.63 (1.24)	6.62 (0.88)	6.99 (0.03)
	range	5 - 11	3 - 7	3 - 7
Sampling rate (second)		60	60	60
Accelerometer type		Micromotion logger		Axivity AX3 wrist-
		sleep watch,	ActiGraph wGT3X-	worn triaxial
		Ambulatory	BT, Pensacola, FL,	accelerometer,
		Monitoring Inc.,	USA	Newcastle
		Ardsley, NY		University, UK

144 Note. All the accelerometer data used in our study were activity count data.

### 145 **Validate CARE with melatonin amplitude**

146 We validated the novel feature CARE by examining its association with the melatonin amplitude in a  
 147 dataset of 33 healthy participants aged 23 - 61 years, where accelerometer activity and melatonin were  
 148 simultaneously collected (**Table 1**). Among the 33 participants, mean CARE was 0.26 ( $SD = 0.05$ ;  
 149 range 0.14 - 0.35), mean relative amplitude was 0.86 ( $SD = 0.07$ ; range 0.67 - 0.96), and mean  
 150 melatonin amplitude was 11.44 pg/ml ( $SD = 6.81$ ; range 1.02 - 28.27). The correlation analysis  
 151 revealed that the melatonin amplitude was only significantly associated with CARE (Pearson's  $r =$   
 152 0.46,  $P = 0.007$ ; **Figure 3a**). On the other hand, we observed no significant association between

153 melatonin amplitude and relative amplitude (Pearson's  $r = 0.24$ ,  $P = 0.19$ ; **Figure 3**) or relative energy  
154 of behavioral noise signals (Pearson's  $r = 0.07$ ,  $P = 0.68$ ; **Figure 3**). Moreover, our study found no  
155 significant association between age and sex with melatonin amplitude ( $P > 0.05$ ; **Supplementary**  
156 **Table 1**). We also found that CARE accounted for 21.16% of the total variance of melatonin amplitude,  
157 whereas age and sex accounted for only 4.3%, and 0.03% of the variance, respectively  
158 (**Supplementary Table 1**).



159 **Figure 3. Correlations between wearable-derived CARE, relative amplitude, and relative energy**  
160 **of behavioral noise with melatonin amplitude.**

161 CARE: circadian activity rhythm energy.

162 Scatter plots between CARE, relative amplitude, and relative energy of behavioral noise in  
163 the melatonin study. The black lines indicate the linear regression fits, and the shaded areas represent the confidence  
164 intervals of the fitted mean values. The correlation coefficients annotated with an asterisk (\*) indicate that the  
165 correlation is significant at  $P < 0.05$  level, while two asterisks (\*\*) indicate that the correlation is significant at  $P <$   
166 0.01 level.

## 167 **Correlation of CARE and cognitive outcomes in adolescents and adults**

168 We applied CARE to two population-based accelerometer datasets with a total of 1,703 adolescents  
169 aged 10-19 years from China and 92,202 adults aged 39-70 years from UK. Characteristics of the  
170 participants and accelerometers data are presented in **Table 1**, and other analyzed variables are  
171 described in **Supplementary Tables 2 and 3**.

172 Mean CARE values were 0.10 (0.04) and 0.13 (0.04) for adolescents and adults, respectively. And  
173 mean relative amplitude values were 0.91 (0.05) and 0.87 (0.06) for adolescents and adults,  
174 respectively. Our results showed that CARE was significantly associated with relative amplitude in  
175 both populations (Pearson's  $r = 0.41$ ,  $P < 0.0001$  for the adolescents; Pearson's correlation  $r: 0.35$ ,  $P <$   
176  $0.0001$  for the adults). Furthermore, we confirmed the internal consistency of CARE by analyzing the  
177 intra-subject versus inter-subject variance. The results showed that the intra-subject variability of  
178 CARE values was not significant in both adolescents ( $P = 0.18$ ) and adults ( $P = 0.25$ ), while the inter-  
179 subject variability was significant in both datasets ( $P < 0.0001$ , **Supplementary Table 4**). Moreover,  
180 we found significant between-group differences in CARE values among individuals with psychiatric  
181 disorders, such as bipolar affective disorder, schizophrenia, depression, and those in the control group  
182 ( $P = 0.02$ , **Supplementary Table 5**).

183 In the adolescent dataset, we used the Behavior Rating Inventory of Executive Function (BRIEF)[38]  
184 to assess adolescent cognitive functions in nature settings, which includes three summary indices,  
185 namely the Behavioral Regulation Index (BRI), the Metacognition Index (MI), and the Global  
186 Executive Composite (GEC). After adjusting confounding factors, the results showed that CARE had  
187 significant associations with GEC scores ( $P = 0.016$ ), but it was not associated with BRI ( $P = 0.10$ )  
188 and MI scores ( $P = 0.03$ ), (see detailed results in **Table 2**). However, no significant association was  
189 found between relative amplitude with any of the cognitive scores ( $P > 0.017$ ) (see detailed results in  
190 **Supplementary Table 6**).

192

193 **Table 2. Associations between CARE and cognitive functions in adolescents.**

Cognitive Scores	n	Coefficient	SE	P Value
<b>BRI</b>	1,703	19.86	11.89	0.10
<b>MI</b>	1,703	24.93	11.57	0.03
<b>GEC</b>	1,703	28.02	11.69	0.016

194 BRI = Behavioral Regulation Index, GEC = Global Executive Composite, MI = Metacognition Index, SE = standard error.  
195 Median regression models were used with adjusting age, sex, parental education level, family income, and primary  
196 caregiver. The significance level was set at  $P < 0.017$ .

197 In the adult dataset, cognitive assessment was conducted via touchscreen cognitive tests, and four main  
198 tasks were considered, i.e., reaction time test assessing processing/reaction speed domain, fluid  
199 intelligence test assessing reasoning ability domain, pairs matching test assessing short-term memory  
200 domain, and prospective memory test assessing prospective memory. We found that CARE showed  
201 significant correlations with reasoning ability, short-term and prospective memory ( $P < 0.0001$ ), but  
202 correlations were not significant for processing/reaction speed ( $P = 0.31$ ). Details regarding the  
203 associations between CARE and cognitive scores are represented in **Table 3**. Though we found that  
204 relative amplitude was correlated with processing/reaction speed ( $P < 0.0001$ ), it was not associated  
205 with reasoning ability, short-term and prospective memory ( $P > 0.013$ ). Details regarding the  
206 associations between relative amplitude and cognitive scores are represented in **Supplementary Table**  
207 **7**.

208 **Table 3. Associations between CARE and cognitive functions in adults.**

Cognitive Scores	n	Coefficient / OR	SE	P Value
<b>Processing/reaction speed</b>	91,830	-8.37	8.22	0.31
<b>Reasoning ability</b>	34,656	0.01	0.003	<0.0001
<b>Short-term memory</b>	77,439	3.42	0.62	<0.0001
<b>Prospective memory</b>	34,173	11.47	6.86	<0.0001

209 OR = odds ratio, SE = standard error. Models were adjusted for age, sex, ethnicity, Townsend score, and the season when  
210 the participant started wearing the accelerometer. Linear regression for processing/reaction speed, ordinal logistic  
211 regression for reasoning ability and short-term memory scores, and logistic regression for prospective memory were  
212 employed. The significance level was set at  $P < 0.013$ .

213 **Causal effects of CARE on cognitive functions**


214 To determine the causal relationship between CARE and cognitive functions, we conducted a GWAS  
215 study of CARE followed with MR analysis in the adult sample, which contains filtered genetic data  
216 for 85,361 people.

217 *1) Genomic locus associated with CARE*

218 One genomic locus on chromosomes 3 was found to correlate with CARE at the genome-wide  
219 significance level of  $5 \times 10^{-8}$ , including 126 single nucleotide polymorphisms (SNPs) (**Figure 4**, lead  
220 variant in **Supplementary Table 8** and all significant associations in **Supplementary Data 1**). The  
221 quantile-quantile (QQ) plot checking for population stratification indicated proper control of  
222 population structure, with a slight deviation in test statistics compared to the null (**Figure 4**,  $\lambda_{GC} = 1.10$ ).  
223 The heritability estimate for CARE was  $>11\%$  ( $h^2_{SNP} = 0.114$ ,  $se = 0.007$ ). This locus was reported to  
224 be associated with common executive functions[39], intelligence[40] and educational attainment[41]  
225 in the previous studies. However, only three SNPs were found to be associated with relative amplitude,  
226 which was too few for causal inference using MR methods (**Supplementary Figure 2** and  
227 **Supplementary Table 9**).

228





229

**Figure 4. Manhattan and QQ plots for CARE in genome-wide association study in the adult sample (n = 85,361).**

(a) The Manhattan plot shows association test ( $-\log_{10} P$  value on the y-axis against physical autosomal location on the x-axis). The red line represents the genome-wide significant locus ( $P < 5 \times 10^{-8}$ ). Heritability estimates were calculated using LDSC tool. (b) The QQ plot identifies a slight inflation ( $\lambda_{GC} = 1.10$ ) in the test statistic.

## 230 2) Causal relationship between CARE and cognitive phenotypes

231 To investigate whether CARE has a causal effect on cognitive outcomes, we performed MR analyses  
232 on significant correlation pairs, i.e., CARE with reasoning ability, short-term and prospective memory  
233 (Table 3). Of the 126 CARE-related SNPs, a total of 109 variants were used as instrumental variables  
234 to conduct the MR analyses. Using the weighted median method, we found that the genetically  
235 predicted CARE had a significant causal effect on reasoning ability ( $\beta = -59.91, P < 0.0001$ ), short-  
236 term ( $\beta = 7.94, P < 0.0001$ ) and prospective memory ( $\beta = 16.85, P < 0.0001$ ). Sensitivity analyses  
237 including inverse variance weighted (IVW)[42], MR-Lasso[43], the mode-based estimate (MBE)[44],  
238 and constrained maximum likelihood-based method (MR-cML)[45] all showed consistent results with  
239 weighted median methods (Supplementary Table 10).

## 240 3) Single-tissue and cross-tissue transcriptome-wide association analysis

241 Single-tissue enrichment analysis identified 120 unique genes associated with CARE ( $P < 2.9 \times 10^{-6}$ )  
242 in 44 GTEx tissues (Supplementary Data 2). Among them, APEH was associated with CARE in 18

243 tissues and was found to correlate with blood protein measurements in previous GWAS studies[46].  
244 TRAIIP was detected in 11 tissues and was reported to be associated with intelligence[39], mental  
245 disorders[47, 48], insomnia[49], blood protein measurement[50, 51], and body mass index[52].  
246 MST1R was associated with CARE in 9 tissues and is related to physical activity measurements[53],  
247 intelligence[54], and body mass index[55]. These correlation results also emphasized shared genetic  
248 architecture between the central nervous system, the metabolic system, and the circadian system.  
249 Furthermore, a total of 15 significant genes were detected using joint-tissue tests for gene-CARE  
250 associations across tissues ( $P < 2.9 \times 10^{-6}$ ; **Supplementary Table 11**).

## 251 **Discussion**

252 In the present study, we proposed a pipeline to derive a novel wearable-based feature (i.e., CARE) to  
253 characterize circadian amplitude and applied it to identify the association between circadian amplitude  
254 and cognitive functions in two large-scale datasets with different age groups. We found a significant  
255 association between CARE and melatonin amplitude (a reliable measure of circadian amplitude), while  
256 relative amplitude (a commonly used amplitude of the activity) was not. Findings that CARE was  
257 associated with a multitude of cognitive outcomes in adolescents and adults demonstrated that CARE  
258 could be a clinically meaningful circadian feature derived from objective accelerometer records.  
259 Furthermore, we identified one genetic locus with 126 SNPs associated with CARE, and provided the  
260 first direct evidence of the causal relations between CARE with reasoning and memory abilities in an  
261 adult sample.

262 Our study found a moderate correlation between the new feature CARE and melatonin amplitude in  
263 general population under natural settings. The use of CARE can effectively eliminate the influence of  
264 behavioral noise on the assessment of circadian amplitude using the accelerometer data, as supported  
265 by the lack of significant association between behavioral noise signals and melatonin amplitude.  
266 Notably, we calculated CARE values using accelerometer activity data of at least 3 days, making it a

267 summary statistic across multiple days for each individual. This computation approach enhances the  
268 stability of CARE values and reduces the intra-subject variability. Nonetheless, it is important to note  
269 that the CARE values may be impacted by data obtained from various accelerometer devices, which  
270 could potentially affect their comparability. Furthermore, the range of CARE values observed in the  
271 melatonin dataset is relatively narrow, which is likely due to the limited range of observed melatonin  
272 amplitude, as the maximum melatonin amplitude can be up to 84 pg/ml in healthy adults[56]. Therefore,  
273 it would be beneficial to investigate whether a broader range of melatonin amplitude leads to a wider  
274 range of CARE values in the future research.

275 The findings that age and sex were not significantly associated with melatonin amplitude may  
276 contradict with previous research that melatonin levels typically decrease with age starting from middle  
277 age and that women tend to have higher melatonin amplitude than men [57-59]. This might be due to  
278 the limited number of middle-aged and elderly participants (age > 40) and the limited sample size in  
279 our dataset. Future research shall recruit larger samples, especially from the elderly adults, to further  
280 examine age and sex differences.

281 Our study demonstrated that CARE and relative amplitude may assess different aspects of circadian  
282 rhythmicity. Although they are all derived from accelerometer data, CARE was designed to reflect the  
283 strength of the core circadian clock located in the SCN, and relative amplitude is more of a metric to  
284 quantify the highest/lowest disruption of rest-activity rhythms. The identification of a sufficient  
285 number of CARE-associated variants can enable us to perform causal inference through MR analysis,  
286 which is not possible with relative amplitude. In addition, the SNP heritability of CARE accounted for  
287 a higher proportion of population variance than relative amplitude in the adult sample (UK Biobank  
288 cohort). These results further supported CARE as a clinically meaningful feature. Future research is  
289 still warranted to systematically compare and assess the relative contribution and relevance of CARE  
290 and relative amplitude, particularly in the context of health and disease.

291 Our study observed a differential association between CARE and cognitive functions in adolescent and  
292 adult groups. In adults, we observed a correlation between CARE and the problem-solving component  
293 of cognitive functions, specifically reasoning and memory domains. However, in adolescents, this  
294 association was not present. This discrepancy may indicate the existence of a compensatory mechanism  
295 in adolescents that counterbalances the impact of circadian rhythm impairments on problem-solving  
296 ability. More research is needed to confirm our hypothesis in the future.

297 In the present study, we demonstrated a causal effect of CARE on reasoning and memory abilities in  
298 adults, and we also provided evidence for the shared genetic architecture of circadian rhythms with  
299 neurological function[9]. The genome-wide significant locus was found to be associated with common  
300 executive functions[39], intelligence[40], and educational attainment[41]. Furthermore, results from  
301 the single-tissue and cross-tissue transcriptome-wide association analyses further confirmed the  
302 CARE's strong biological basis and highlighted the important role of circadian rhythms on the central  
303 nervous system, which is in line with previous findings from the other UK Biobank studies[60].

304 In conclusion, the new feature CARE that we derived from accelerometer data, is closely related to  
305 the melatonin amplitude in natural settings, and also serves as a meaningful metric for a wide range  
306 of cognitive functions in general adolescents and adults. Future studies with large sample size and  
307 different protocols such as forced desynchrony settings and shift work should be conducted to  
308 validate the new feature CARE and to confirm its causality on other health-related outcomes.

## 309 **Methods**

### 310 **The melatonin dataset**

#### 311 *Participants*

312 This dataset recruited 33 healthy adults (17 male and 16 female) aged 23-61 years in January 2023.  
313 Prior to enrollment, all participants underwent screening to exclude the use of sleep aid supplements  
314 (e.g., melatonin), a history of shift work, and sleep disorders. The participants were asked to complete

315 a range of demographic, lifestyle, and health related questionnaires, to wear an accelerometer, and to  
316 collect saliva samples with 5 times. This protocol was approved by the Shanghai Children's Medical  
317 Center's Human Ethics Committee (SCMCIRB-K2021070-2) and Shanghai Jiao Tong University  
318 School of Medicine (SJTUPN-202301). All participants provided digital written informed consent.

### 319 *Accelerometer data collection and processing*

320 The participants were asked to wear an accelerometer (Micromotion logger sleep watch, Ambulatory  
321 Monitoring Inc., Ardsley, NY) on their non-dominant wrist for nine consecutive days, meanwhile, they  
322 were required to keep a diary recording bedtime, rise time, and off-wrist period on each day. They were  
323 informed not to remove the device unless engaged in special activities (e.g., showering), and to re-wear  
324 it immediately after the activities were finished. We defined the daytime period as 08:00-20:00 and the  
325 nighttime period as 20:00-08:00. According to the diary recording for the off-wrist periods, we defined  
326 a criterion that at least 15 min of consecutive zero counts were identified nonwear periods in period  
327 08:00-23:00, and at least 3 hours of consecutive zero counts were identified nonwear periods in the  
328 remaining period. We also considered that the valid data on each day should meet at least 20 hours (i.e.,  
329 more than 83% of the whole 24 hours) of wearing time without more than three consecutive hours of  
330 missing data. If less than 3 hours of missing data existed, we used the mean of the corresponding time  
331 points on the other days to fill the gaps. After checking, if there were still missing values (often due to  
332 the missing data being at a fixed time every day, so it could not be filled using the mean value), the  
333 average of physical activity counts around the missing area (i.e., about 6 epoch) was used to fill. After  
334 preprocessing the invalid and missing raw data, each individual included should have at least three  
335 valid days of data, and the activity counts with 1-min resolution were used to calculate the new feature  
336 CARE using the above-proposed novel pipeline and to compute the commonly used feature relative  
337 amplitude by the difference between the average activity level of an individual during the most active  
338 consecutive ten hours (M10) and the least active consecutive five hours of the day (L5).

339 
$$\text{Relative amplitude} = \frac{M_{10} - L_5}{M_{10} + L_5}$$

340 *Saliva melatonin data collection and processing*

341 We used the Salivettes<sup>®</sup> (Sarstedt, Nümbrecht, Germany) to collect saliva. On the eighth and ninth day  
342 of wearing the accelerometer, the participants were asked to collect 2 ml saliva samples 5 times (i.e.,  
343 9 am, 15 pm, 21 pm, 3 am, and 9 am of the next day; time window  $\pm 1$  hour) across 24 hours, of which  
344 the saliva sample at 21 pm and 3 am were required to be collected under the dark light (light intensity  
345  $< 30$  lux) if the participants usually went to sleep at that time. The participants were informed to follow  
346 their usual sleep schedule and don't intake caffeine, alcohol, and fatty foods on the sampling day, keep  
347 their mouth clean (e.g., food intake restriction) in the 30 min prior to sampling, and do not swallow  
348 saliva while chewing the swab. They were also informed to store each sample immediately in the  
349 freezer layer of the refrigerator after collection, and to transfer all of the samples to the laboratory using  
350 ice packs. Subsequently, after centrifugation at 4°C for 10 min at 3000 rpm, the supernatant saliva  
351 samples were collected into 2 ml EP tube and stored at -80°C until use.

352 Saliva melatonin was measured by liquid chromatography-tandem mass spectrometry, which can  
353 quantify the range of the melatonin from 1 to 1000 pg/ml, and only use small volume of the saliva  
354 samples (100  $\mu$ l). Detailed measurement was similar to the quantification of melatonin in human  
355 milk[61]. For more information, please contact the corresponding author. After quantification of saliva  
356 melatonin levels, we checked the extreme values, and we excluded the values less than 2 pg/ml which  
357 collected at 3 am (time window  $\pm 1$  hour). And then melatonin profiles were obtained by linear  
358 interpolation and curve fitting using skewed baseline cosine function (SBCF) (**Supplementary Figure**  
359 **3**), a robust model for melatonin estimation when there were limited time points in the collection of  
360 melatonin[62].

361 **The adolescent dataset**

362 *Participants*

363 The Shanghai Children's Health, Education, and Lifestyle Evaluation-Adolescent (SCHEDULE-A) is  
364 a population-based cross-sectional study designed to investigate the physical and mental health of  
365 adolescents (10-19 years). A total of 1,703 adolescents from a subsample of SCHEDULE-A (Shanghai  
366 city, China) were utilized for this study. Two data acquisition schemes, an online questionnaire survey,  
367 and offline accelerometer wearing, were performed simultaneously to collect adolescents' socio-  
368 demographic information, lifestyle behaviors, physical and mental health outcomes. Details of the  
369 protocol can be found in one prior published study[63]. This study was approved by the Human Ethics  
370 Committee of the Shanghai Children's Medical Center according to the Declaration of Helsinki  
371 (SCMCIRB-K2018103). Written informed consent was obtained from all participants.

#### 372 *Accelerometer data collection and processing*

373 Participants were asked to wear an accelerometer (ActiGraph wGT3X-BT, Pensacola, FL, USA) on  
374 the non-dominant wrist for seven consecutive days. The other requirements including device wearing  
375 and diary recording were similar to the melatonin dataset. Using the same way to preprocess the raw  
376 data, and then CARE and relative amplitude were calculated.

#### 377 *Measurement of cognitive functions*

378 The Chinese version of the BRIEF was used to assess adolescent cognitive functions in nature  
379 settings[64]. The BRIEF has 86 items, each one is rated on a three-point Likert-type scale, including  
380 never, sometimes and often, and parents of the participants were asked to select the most suitable  
381 answer for their adolescents in the past 6 months. After cleaning the raw data[63], three indexes were  
382 calculated: 1) the BRI, represents the ability to modulate behavioral and emotional responses  
383 appropriately; 2) the MI, evaluates the ability to solve problems, including initiating activities and tasks,  
384 holding information in mind for purpose of completing a task, anticipating future events, monitoring  
385 the effects of one's behaviors on others and keeping track of daily assignments; 3) the GEC, is a  
386 composite measure of all the cognitive functions mentioned above. Values of BRIEF scores reflect the

387 extent of impairment of the corresponding cognitive functions, and higher scores indicate greater  
388 impairments.

### 389 *Covariates*

390 One of the participants' parents was asked to complete a questionnaire about their social-demographic  
391 characteristics, i.e., adolescents' age, sex, primary caregiver (parents/grandparents or others), family  
392 income (< 50,000 CNY/year, 50,000 to 150,000 CNY/year,  $\geq$  150,000 CNY/year), and parental  
393 education level (below high school, high school, college and above).

## 394 **The adult dataset**

### 395 *Participants*

396 The UK Biobank cohort is a general longitudinal study with over 500,000 participants recruited from  
397 the United Kingdom (UK). In the current study, we selected 92,202 participants who provided qualified  
398 accelerometer data for at least three days after data preprocessing and who had complete records in age  
399 and sex. The demographic, lifestyle, health, mood, cognitive, and physical conditions of the  
400 participants were collected at 22 assessment centers. The UK Biobank has received ethical approval  
401 from the North-West Research Ethics Committee (11/NW/03820) and all participants gave written  
402 informed consent.

### 403 *Accelerometer data collection and processing*

404 Participants were asked to wear an accelerometer (Activity AX3 wrist-worn triaxial accelerometer,  
405 Newcastle University, UK) for seven consecutive days. The accelerometer raw data were preprocessed  
406 similarly to the above melatonin and adolescent datasets. Participants were also excluded if their data  
407 were identified by UK Biobank as poorly calibrated ( $n = 11$ ) or unreliable (unexpectedly small or large  
408 size,  $n = 4,692$ ). Participants who provided accelerometer data for less than 72 hours or who did not  
409 provide data for all one-hour periods within the 24-h cycle ( $n = 4,465$ ) were also excluded from further  
410 analyses. Similarly, after cleaning the raw data, CARE and relative amplitude were calculated.

### 411 *Measurement of cognitive functions*



412 Four tests were used to assess adult processing/reaction speed, reasoning ability, short-term memory,  
413 and prospective memory. 1) The processing/reaction speed was assessed by the reaction time test.  
414 During the test, participants were shown 12 pairs of images of cards for 12 rounds, and they pressed  
415 the button on the touchscreen when the two cards are the same. The processing/reaction speed was then  
416 calculated by the mean reaction time of the correct matches over the last 7 rounds after the exclusion  
417 of times below 50ms and above 2,000ms. Due to negative skewness in reaction time, we performed  
418 the analyses using both the raw and log-transformed data form. Since the results were equivalent, only  
419 the results of raw reaction time were reported for ease of interpretation. 2) Reasoning ability was  
420 measured by the fluid intelligence tests. Participants were asked to answer 13 fluid intelligence  
421 questions within 2 minutes and the total number of correct answers to these questions was recorded as  
422 the fluid intelligence score. 3) Short-term memory was assessed by the pairs matching tests.  
423 Participants were asked to memorize as many pairs of cards as possible within the time the cards were  
424 shown. Then the cards were turned face down and the participants were asked to match the cards. The  
425 test was conducted in two rounds, with 3 and 6 pairs of cards presented in each round. The outcome  
426 measure used in this study was the number of incorrect matches in rounds, as suggested by the UK  
427 Biobank website. 4) Prospective memory was assessed by the prospective memory test. Before the  
428 other touchscreen cognitive tests, the participant was shown the message "At the end of the games we  
429 will show you four colored shapes and ask you to touch the Blue Square. However, to test your memory,  
430 we want you to actually touch the Orange Circle instead". The results were divided into 3 categories,  
431 0 for instruction not recalled, 1 for correct recall on the first attempt, and 2 for correct recall on the  
432 second attempt, respectively. The outcome measure used in this study was the number of attempts  
433 before getting the correct recall.

#### 434 *Covariates*

435 Participants provided data on demographic characteristics including age, sex, ethnicity, educational  
436 attainment, and lifestyle at the baseline assessment. Townsend's social deprivation score is defined

437 based on the postcode of residence, with negative scores reflecting relatively greater affluence. The  
438 season when the participant started to wear the accelerometer was derived from raw accelerometer  
439 records, i.e., spring for March to May, summer for June to August, autumn for September to November,  
440 and winter for December to February according to the UK Meteorological Office definitions.

#### 441 **Statistical analysis**

442 The characteristics of the three datasets were described by mean (*SD* and range), and frequency (%)  
443 for continuous and categorical variables, respectively. To address our purpose, the following three  
444 steps were conducted after calculating the new feature CARE according to the above-proposed pipeline  
445 (**Figure 1**).

446 **Step one:** to validate the novel wearable-derived feature CARE

447 We firstly calculated the new feature CARE using the above-proposed pipeline from accelerometer  
448 data. Secondly, using the same pipeline, we also derived the relative energy of behavioral noise signals  
449 (sub-signals with a period less than 24 hours) from accelerometer activity data:

$$450 \quad \text{Relative energy of behavioral signals} = \frac{\text{energy of behavioral noise signal}}{\text{total energy of activity signal}} = \frac{\sum_{u \in U} \|X_u\|_F^2}{\|X\|_F^2},$$

451 where  $\|X_u\|_F^2$  is Frobenius norm of the  $u$ th sub-signal,  $U$  is the subset of indices corresponding to the  
452 behavioral noise signal (sub-signals with a period  $< 24$ h), and  $\|X\|_F^2$  is Frobenius norm of the raw  
453 activity signal. Thirdly, we obtained the melatonin profiles by linear interpolation and curve fitting  
454 using skewed baseline cosine function (SBCF), a robust model for melatonin estimation when there  
455 were limited time points[62]; Fourthly, the melatonin amplitude was measured by subtraction of the  
456 maximum and minimum values of the melatonin secretion curve; and finally, we conducted Pearson  
457 correlation analyses between CARE, relative amplitude, and the relative energy of behavioral high-  
458 frequency signals with melatonin amplitude. Additionally, we examined the associations between  
459 CARE and melatonin amplitude while adjusting for age and sex.

460 **Step two:** to determine the correlation relationship of CARE with multitude of cognitive functions in  
461 adolescents and adults

462 Prior to performing the association analysis, we evaluated the internal stability of CARE values through  
463 two distinct analyses. Firstly, we randomly selected a subset of 1,000 individuals each from the  
464 adolescent and adult datasets who had at least six days of accelerometer data. We then calculated the  
465 CARE values using the first three days of recordings (repetition 1) and the fourth to sixth days of  
466 recordings (repetition 2), respectively. An Analysis of Variance (ANOVA) was then performed to  
467 compare the intra-subject and inter-subject variability of CARE values. Secondly, we conducted  
468 another ANOVA to explore the within-group and between group variability of CARE values in bipolar  
469 affective disorder (n = 147), schizophrenia (n = 42), depression (n = 2,252), and control groups (n =  
470 36,315) in the adult dataset. Specifically, the control group comprised individuals who did not currently  
471 have the above-mentioned psychiatric diseases, did not have a history of mental disease, did not take  
472 psychiatric medication, did not receive any professional help for mental distress, and had not suffered  
473 from mental distress.

474 We then performed different regression models to determine the relationship of CARE with multitude  
475 of cognitive functions in two datasets. Specifically, in adolescents, because all the three BRIEF indices  
476 (i.e., BRI, MI, and GEC) were skewed distributed, median regression analysis was used with  
477 adjustment for the demographic variables (i.e., age, sex, parental education level, family income, and  
478 primary caregiver); and in adults, linear regression model was performed to assess the associations  
479 between CARE and processing/reaction speed, ordinal logistic regression model was employed to  
480 investigate the associations between CARE and count outcome variables (reasoning ability, and short-  
481 term memory), while logistic regression model was conducted to test the correlation between CARE  
482 and the binary cognitive measures of prospective memory. Similarly, models were adjusted for age,  
483 sex, ethnicity, Townsend score, and the season when the participant started wearing the accelerometer.  
484 To maximize sample sizes, available-case analyses were employed, and sample sizes for each model

485 were reported. Moreover, the analyses mentioned above were also performed on relative amplitude for  
486 the purpose of comparison.

487 All analyses were performed in R 4.1.2, and the threshold for significance was set at  $P < 0.05/3 = 0.017$   
488 (3 cognitive outcomes) and  $P < 0.05/4 = 0.013$  (4 cognitive outcomes) to correct for multiple testing  
489 according to Bonferroni's approach in adolescent and adult dataset analyses, respectively.

490 ***Step three:*** to identify the causal relationship between CARE and cognitive functions in the adult  
491 dataset.

#### 492 *1) Identification of loci associated with CARE*

493 Before the genetic analysis, we excluded SNPs with Minor Allele Frequency  $< 0.1\%$ , Hardy-Weinberg  
494 equilibrium  $< 1 \times 10^{-10}$ , and imputation quality score (UKBB information score)  $< 0.8$ . Furthermore,  
495 for related individuals (first cousins or closer), one individual from each pair of related individuals was  
496 randomly selected for inclusion in the analysis, and non-white individuals were also removed from the  
497 analysis. After data filtering, a total of 85,361 samples remained for further analysis. To identify  
498 genetic variants associated with CARE, we performed a GWAS analysis using PLINK[65]. Linear  
499 regression models were adjusted by age, sex, and the first 20 genetic principal components, and the  
500 genome-wide significance level was set at  $5 \times 10^{-8}$ . To estimate SNP heritability ( $h^2_{\text{SNP}}$ ), the Linkage  
501 Disequilibrium Score Regression (LDSR) was applied to the GWAS summary statistics of CARE with  
502 the LDSC tool[66, 67]. Furthermore, we identified one significant locus that was associated with the  
503 relative amplitude, however, only three SNPs were found, which was just too little that we couldn't  
504 conduct the further causal analysis.

#### 505 *2) Causal relationship between CARE and cognitive functions*

506 To investigate the causal relationship between CARE and cognitive functions, we conducted MR  
507 analyses using the R package "MendelianRandomization"[68]. In order to exclude instrumental  
508 variables with weak power, we pruned CARE-related SNPs and finally determined 109 SNPs as  
509 instruments. To avoid inflation of associations caused by the sample overlap, genetic effect sizes for

510 reasoning ability, short-term and prospective memory were obtained from GWAS analysis after  
511 excluding all individuals used in the GWAS analysis of CARE (n = 360,885). In the MR analyses, the  
512 weighted median approach[69] was used as the main analysis due to its robustness to pleiotropy [70].  
513 Furthermore, we applied inverse variance weighted (IVW)[42], MR-Lasso[43], the mode-based  
514 estimate (MBE)[44], and constrained maximum likelihood-based method (MR-cML)[45] to perform  
515 sensitivity analyses. The beta coefficients were reported and Bonferroni-adjusted *P* values less than  
516 0.017 (3 outcomes) were considered evidence of associations.

### 517 *3) Single-tissue and Cross-tissue Transcriptome-wide Association Analysis*

518 In addition, we examined the biological and functional mechanisms underlying CARE by performing  
519 transcriptome-wide analysis in 44 tissue types in GTEx v7. We identified single-tissue and cross-tissue  
520 gene-CARE associations based on GWAS summary statistics and expression quantitative trait loci  
521 (eQTL) information, using UTMOST[71]. The Bonferroni-corrected threshold for significance in  
522 UTMOST is  $2.9 \times 10^{-6}$  for 17,290 genes.

### 523 **Data Availability**

524 The melatonin and adolescent datasets used in the current study are not publicly available but are  
525 available from the corresponding author (Fan Jiang) on reasonable request. The UK Biobank data that  
526 support the findings of this study are available from the UK Biobank project but restrictions apply to  
527 the availability of these data, which were used under license for the current study (application number:  
528 57947), and so are not publicly available.

### 529 **Code Availability**

530 Codes for calculating CARE were publicly available at <https://github.com/ShuyaCui/CARE>.

### 531 **References**

- 532 1. Foster, R.G. and L. Kreitzman, *The rhythms of life: what your body clock means to you!* Exp  
533 Physiol, 2014. **99**(4): p. 599-606.
- 534 2. Dibner, C. and U. Schibler, *Circadian timing of metabolism in animal models and humans.*  
535 Journal of Internal Medicine, 2015. **277**(5): p. 513-527.

- 536 3. Zimmet, P., et al., *The Circadian Syndrome: is the Metabolic Syndrome and much more!*  
537 *Journal of Internal Medicine*, 2019. **286**(2): p. 181-191.
- 538 4. Chowdhury, D., et al., *Understanding Quantitative Circadian Regulations Are Crucial*  
539 *Towards Advancing Chronotherapy*. *Cells*, 2019. **8**(8): p. 883.
- 540 5. Refinetti, R., *Circadian rhythmicity of body temperature and metabolism*. *Temperature*, 2020.  
541 **7**(4): p. 321-362.
- 542 6. Welsh, D.K., J.S. Takahashi, and S.A. Kay, *Suprachiasmatic Nucleus: Cell Autonomy and*  
543 *Network Properties*. *Annual Review of Physiology*, 2010. **72**(1): p. 551-577.
- 544 7. Buhr, E.D. and J.S. Takahashi, *Molecular components of the Mammalian circadian clock*.  
545 *Handb Exp Pharmacol*, 2013(217): p. 3-27.
- 546 8. Schibler, U., et al., *Clock-Talk: Interactions between Central and Peripheral Circadian*  
547 *Oscillators in Mammals*. *Cold Spring Harbor Symposia on Quantitative Biology*, 2015. **80**: p.  
548 223-232.
- 549 9. Leng, Y., et al., *Association between circadian rhythms and neurodegenerative diseases*. *The*  
550 *Lancet Neurology*, 2019. **18**(3): p. 307-318.
- 551 10. Costa, M.J., et al., *Inference on periodicity of circadian time series*. *Biostatistics*, 2013. **14**(4):  
552 p. 792-806.
- 553 11. Li, X., et al., *Circadian Rhythm Analysis Using Wearable Device Data: Novel Penalized*  
554 *Machine Learning Approach*. *Journal of Medical Internet Research*, 2021. **23**(10): p. e18403.
- 555 12. Kolodyazhniy, V., et al., *Estimation of Human Circadian Phase via a Multi-Channel*  
556 *Ambulatory Monitoring System and a Multiple Regression Model*. *Journal of Biological*  
557 *Rhythms*, 2011. **26**(1): p. 55-67.
- 558 13. Kolodyazhniy, V., et al., *An improved method for estimating human circadian phase derived*  
559 *from multichannel ambulatory monitoring and artificial neural networks*. *Chronobiol Int*,  
560 2012. **29**(8): p. 1078-97.
- 561 14. Stone, J.E., et al., *Generalizability of A Neural Network Model for Circadian Phase*  
562 *Prediction in Real-World Conditions*. *Sci Rep*, 2019. **9**(1): p. 11001.
- 563 15. Brown, L.S., et al., *A classification approach to estimating human circadian phase under*  
564 *circadian alignment from actigraphy and photometry data*. *Journal of Pineal Research*, 2021.  
565 **71**(1).
- 566 16. Cheng, P., et al., *Predicting circadian misalignment with wearable technology: validation of*  
567 *wrist-worn actigraphy and photometry in night shift workers*. *Sleep*, 2021. **44**(2).
- 568 17. Stone, J.E., et al., *Computational approaches for individual circadian phase prediction in*  
569 *field settings*. *Current Opinion in Systems Biology*, 2020. **22**: p. 39-51.
- 570 18. Dijk, D.J. and J.F. Duffy, *Novel Approaches for Assessing Circadian Rhythmicity in Humans:*  
571 *A Review*. *J Biol Rhythms*, 2020. **35**(5): p. 421-438.
- 572 19. Jewett, M.E., R.E. Kronauer, and C.A. Czeisler, *Light-induced suppression of endogenous*  
573 *circadian amplitude in humans*. *Nature*, 1991. **350**(6313): p. 59-62.
- 574 20. Dijk, D.-J., et al., *Amplitude Reduction and Phase Shifts of Melatonin, Cortisol and Other*  
575 *Circadian Rhythms after a Gradual Advance of Sleep and Light Exposure in Humans*. *PLOS*  
576 *ONE*, 2012. **7**(2): p. e30037.

- 577 21. Benloucif, S., et al., *Measuring Melatonin in Humans*. Journal of Clinical Sleep Medicine,  
578 2008. **04**(01): p. 66-69.
- 579 22. Witting, W., et al., *Alterations in the circadian rest-activity rhythm in aging and Alzheimer's*  
580 *disease*. Biological Psychiatry, 1990. **27**(6): p. 563-572.
- 581 23. Leise, T.L., *Wavelet analysis of circadian and ultradian behavioral rhythms*. Journal of  
582 Circadian Rhythms, 2013. **11**(0): p. 5.
- 583 24. Ancoli-Israel, S., et al., *The role of actigraphy in the study of sleep and circadian rhythms*.  
584 Sleep, 2003. **26**(3): p. 342-92.
- 585 25. Heyde, I., J.-T. Kiehn, and H. Oster, *Mutual influence of sleep and circadian clocks on*  
586 *physiology and cognition*. Free Radical Biology and Medicine, 2018. **119**: p. 8-16.
- 587 26. Taillard, J., et al., *Sleep timing, chronotype and social jetlag: Impact on cognitive abilities*  
588 *and psychiatric disorders*. Biochemical Pharmacology, 2021. **191**: p. 114438.
- 589 27. Wang, M., et al., *Altered Biological Rhythm and Alzheimer's Disease: A Bidirectional*  
590 *Relationship*. CURRENT ALZHEIMER RESEARCH, 2021. **18**(9): p. 667-675.
- 591 28. Tranah, G.J., et al., *Circadian activity rhythms and risk of incident dementia and mild*  
592 *cognitive impairment in older women*. Annals of Neurology, 2011. **70**(5): p. 722-732.
- 593 29. Kessler, R.C., et al., *Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV*  
594 *Disorders in the National Comorbidity Survey Replication*. Archives of General Psychiatry,  
595 2005. **62**(6): p. 593-602.
- 596 30. Hagenauer, M.H. and T.M. Lee, *The neuroendocrine control of the circadian system:*  
597 *adolescent chronotype*. Front Neuroendocrinol, 2012. **33**(3): p. 211-29.
- 598 31. Doherty, A., *Circadian rhythms and mental health: wearable sensing at scale*. The Lancet  
599 Psychiatry, 2018. **5**(6): p. 457-458.
- 600 32. Lyall, L.M., et al., *Association of disrupted circadian rhythmicity with mood disorders,*  
601 *subjective wellbeing, and cognitive function: a cross-sectional study of 91 105 participants*  
602 *from the UK Biobank*. Lancet Psychiatry, 2018. **5**(6): p. 507-514.
- 603 33. Ferguson, A., et al., *Genome-Wide Association Study of Circadian Rhythmicity in 71,500 UK*  
604 *Biobank Participants and Polygenic Association with Mood Instability*. EBioMedicine, 2018.  
605 **35**: p. 279-287.
- 606 34. Hassani, H., *Singular Spectrum Analysis: Methodology and Comparison*. University Library  
607 of Munich, Germany, MPRA Paper, 2007. **5**.
- 608 35. Hassani, H., et al., *On the Separability between Signal and Noise in Singular Spectrum*  
609 *Analysis*. Fluctuation and Noise Letters, 2012. **11**(02).
- 610 36. Leise, T.L., et al., *Wavelet Meets Actogram*. Journal of Biological Rhythms, 2013. **28**(1): p.  
611 62-68.
- 612 37. Doherty, A., et al. *Large Scale Population Assessment of Physical Activity Using Wrist Worn*  
613 *Accelerometers: The UK Biobank Study*. PloS one, 2017. **12**, e0169649 DOI:  
614 10.1371/journal.pone.0169649.
- 615 38. Gioia, G.A., P.K. Isquith, and R.M. Roth, *Behavior Rating Inventory for Executive Function,*  
616 *in Encyclopedia of Clinical Neuropsychology*, J.S. Kreutzer, J. DeLuca, and B. Caplan,  
617 Editors. 2018, Springer International Publishing: Cham. p. 532-538.

- 618 39. Hatoum, A.S., et al., *Genome-wide Association Study Shows That Executive Functioning Is*  
619 *Influenced by GABAergic Processes and Is a Neurocognitive Genetic Correlate of*  
620 *Psychiatric Disorders*. *Biol Psychiatry*, 2023. **93**(1): p. 59-70.
- 621 40. Hill, W.D., et al., *Genome-wide analysis identifies molecular systems and 149 genetic loci*  
622 *associated with income*. *Nat Commun*, 2019. **10**(1): p. 5741.
- 623 41. Davies, G., et al., *Genome-wide association study of cognitive functions and educational*  
624 *attainment in UK Biobank (N=112 151)*. *Mol Psychiatry*, 2016. **21**(6): p. 758-67.
- 625 42. Burgess, S., A. Butterworth, and S.G. Thompson, *Mendelian Randomization Analysis With*  
626 *Multiple Genetic Variants Using Summarized Data*. *GENETIC EPIDEMIOLOGY*, 2013.  
627 **37**(7): p. 658-665.
- 628 43. Rees, J.M.B., et al., *Robust methods in Mendelian randomization via penalization of*  
629 *heterogeneous causal estimates*. *PLoS One*, 2019. **14**(9): p. e0222362.
- 630 44. Hartwig, F.P., G. Davey Smith, and J. Bowden, *Robust inference in summary data Mendelian*  
631 *randomization via the zero modal pleiotropy assumption*. *Int J Epidemiol*, 2017. **46**(6): p.  
632 1985-1998.
- 633 45. Xue, H., X. Shen, and W. Pan, *Constrained maximum likelihood-based Mendelian*  
634 *randomization robust to both correlated and uncorrelated pleiotropic effects*. *Am J Hum*  
635 *Genet*, 2021. **108**(7): p. 1251-1269.
- 636 46. Barton, A.R., et al., *Whole-exome imputation within UK Biobank powers rare coding variant*  
637 *association and fine-mapping analyses*. *Nat Genet*, 2021. **53**(8): p. 1260-1269.
- 638 47. Adewuyi, E.O., et al., *A large-scale genome-wide cross-trait analysis reveals shared genetic*  
639 *architecture between Alzheimer's disease and gastrointestinal tract disorders*. *Commun Biol*,  
640 2022. **5**(1): p. 691.
- 641 48. Rao, S., et al., *Genetic Relationships between Attention-Deficit/Hyperactivity Disorder,*  
642 *Autism Spectrum Disorder, and Intelligence*. *Neuropsychobiology*, 2022. **81**(6): p. 484-496.
- 643 49. Jansen, P.R., et al., *Genome-wide analysis of insomnia in 1,331,010 individuals identifies new*  
644 *risk loci and functional pathways*. *Nat Genet*, 2019. **51**(3): p. 394-403.
- 645 50. Ligthart, S., et al., *Genome Analyses of >200,000 Individuals Identify 58 Loci for Chronic*  
646 *Inflammation and Highlight Pathways that Link Inflammation and Complex Disorders*. *Am J*  
647 *Hum Genet*, 2018. **103**(5): p. 691-706.
- 648 51. Oskarsson, G.R., et al., *Predicted loss and gain of function mutations in ACO1 are associated*  
649 *with erythropoiesis*. *Commun Biol*, 2020. **3**(1): p. 189.
- 650 52. Zhu, Z., et al., *Shared genetic and experimental links between obesity-related traits and*  
651 *asthma subtypes in UK Biobank*. *J Allergy Clin Immunol*, 2020. **145**(2): p. 537-549.
- 652 53. Wang, Z., et al., *Genome-wide association analyses of physical activity and sedentary*  
653 *behavior provide insights into underlying mechanisms and roles in disease prevention*. *Nat*  
654 *Genet*, 2022. **54**(9): p. 1332-1344.
- 655 54. Savage, J.E., et al., *Genome-wide association meta-analysis in 269,867 individuals identifies*  
656 *new genetic and functional links to intelligence*. *Nat Genet*, 2018. **50**(7): p. 912-919.
- 657 55. Pulit, S.L., et al., *Meta-analysis of genome-wide association studies for body fat distribution*  
658 *in 694 649 individuals of European ancestry*. *Hum Mol Genet*, 2019. **28**(1): p. 166-174.



- 659 56. Burgess, H.J. and L.F. Fogg, *Individual Differences in the Amount and Timing of Salivary*  
660 *Melatonin Secretion*. PLoS ONE, 2008. **3**(8): p. e3055.
- 661 57. Zhou, J.-N., et al., *Alterations in the circadian rhythm of salivary melatonin begin during*  
662 *middle-age*. Journal of Pineal Research, 2003. **34**(1): p. 11-16.
- 663 58. Hardeland, R., et al., *Melatonin—A pleiotropic, orchestrating regulator molecule*. Progress in  
664 *Neurobiology*, 2011. **93**(3): p. 350-384.
- 665 59. Cain, S.W., et al., *Sex differences in phase angle of entrainment and melatonin amplitude in*  
666 *humans*. Journal of biological rhythms, 2010. **25**(4): p. 288-296.
- 667 60. Li, X. and H. Zhao, *Automated feature extraction from population wearable device data*  
668 *identified novel loci associated with sleep and circadian rhythms*. PLOS Genetics, 2020.  
669 **16**(10): p. e1009089.
- 670 61. Jin, W., et al., *High-throughput quantitation of trace level melatonin in human milk by on-line*  
671 *enrichment liquid chromatography-tandem mass spectrometry*. Anal Chim Acta, 2021. **1176**:  
672 p. 338764.
- 673 62. Van Someren, E.J.W. and E. Nagtegaal, *Improving melatonin circadian phase estimates*.  
674 2007. **8**(6): p. 590-601.
- 675 63. Lin, Q., et al., *Weight spectrum and executive function in adolescents: the moderating role of*  
676 *negative emotions*. Child Adolesc Psychiatry Ment Health, 2022. **16**(1): p. 34.
- 677 64. Qian, Y. and Y.F. Wang, *[Reliability and validity of behavior rating scale of executive*  
678 *function parent form for school age children in China]*. Beijing Da Xue Xue Bao Yi Xue  
679 Ban, 2007. **39**(3): p. 277-83.
- 680 65. Chang, C.C., et al., *Second-generation PLINK: rising to the challenge of larger and richer*  
681 *datasets*. Gigascience, 2015. **4**: p. 7.
- 682 66. Bulik-Sullivan, B.K., et al., *LD Score regression distinguishes confounding from polygenicity*  
683 *in genome-wide association studies*. Nat Genet, 2015. **47**(3): p. 291-5.
- 684 67. Gazal, S., et al., *Linkage disequilibrium-dependent architecture of human complex traits*  
685 *shows action of negative selection*. Nature Genetics, 2017. **49**(10): p. 1421-1427.
- 686 68. Yavorska, O.O. and S. Burgess, *MendelianRandomization: an R package for performing*  
687 *Mendelian randomization analyses using summarized data*. Int J Epidemiol, 2017. **46**(6): p.  
688 1734-1739.
- 689 69. Bowden, J., et al., *Consistent Estimation in Mendelian Randomization with Some Invalid*  
690 *Instruments Using a Weighted Median Estimator*. GENETIC EPIDEMIOLOGY, 2016. **40**(4):  
691 p. 304-314.
- 692 70. Bowden, J. and M.V. Holmes, *Meta-analysis and Mendelian randomization: A review*.  
693 *Research Synthesis Methods*, 2019. **10**(4): p. 486-496.
- 694 71. Hu, Y., et al., *A statistical framework for cross-tissue transcriptome-wide association*  
695 *analysis*. Nature Genetics, 2019. **51**(3): p. 568-576.

696 **Acknowledgements**

697 The study was supported by the National Key R&D Program of China (2018YFC0910500), National  
698 Natural Science Foundation of China (82073568), Shanghai Jiao Tong University (YG2016ZD04),  
699 Shanghai Municipal Health Commission (GWIV-36 and GWV-10.1-XK07), SJTU-Yale Collaborative  
700 Research Seed Fund, the Neil Shen's SJTU Medical Research, and Innovative Research Team of High-  
701 level Local Universities in Shanghai (SHSMU-ZDCX20211900). The melatonin and adolescent  
702 datasets were kindly provided by the Shanghai Children's Medical Center. The authors are grateful to  
703 all members for contributing data to the two databases. This research was also conducted with the UK  
704 Biobank resource, under application 57947. We thank all individuals involving in the UK Biobank  
705 study. Additionally, we extend our gratitude to Du Jingyu for his assistance in refining the language of  
706 the manuscript.

#### 707 **Author contributions**

708 Conceptualization: CS, LQ; Data curation: CS, LQ; Formal analysis: CS, GY; Funding acquisition:  
709 LH, JF; Investigation: CS, LQ, ZY; Methodology: CS, LQ, ZH, LX; Project administration: ZY, JF;  
710 Resources: LH, JF; Supervision: LH, ZH, WX, LX, JF; Validation: CS, LQ, GY; Visualization: CS;  
711 Writing——original draft: CS; Writing——review & editing: CS, LQ, GY, ZY, LH, ZH, WX, LX,  
712 JF. All authors read and approved the final manuscript.

#### 713 **Ethics Declaration**

#### 714 **Competing interests**

715 The authors declare no competing interests.